Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Lykos CEO to depart after FDA rejection, layoffs
Lykos Therapeutics CEO Amy Emerson to step down after FDA rejection of MDMA therapy aid approval. Michael Mullette appointed interim CEO. Company plans to cut 75% of workforce and resubmit MDMA approval application.
FDA's new drug approvals in August include a Dupixent competitor, a targeted glioma ...
FDA approved seven new therapies in August, including a competitor to Dupixent for prurigo nodularis, Gilead’s PPARδ agonist, and targeted cancer therapies.
Biotechnology Market: CAGR of 14.2% Trends, Share Metrics
The Global Biotechnology Market, valued at USD 1,094.6 Billion in 2024, is projected to reach USD 2772.7 Billion by 2032, with a CAGR of 14.2%. The market report includes detailed analysis, key players, and segments such as applications and technologies, with regional assessments covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Roche's BTK inhibitor shines in multiple sclerosis trial
Roche's Phase II study of BTK inhibitor fenebrutinib shows 96% of RMS patients relapse-free at one year, with no disability change and 99% free of T1-Gd+ lesions. The safety profile remains consistent, with ongoing Phase III trials expected to validate these results.
Related Clinical Trials:
After Initial Stumbles, Tolebrutinib Achieves Primary Endpoint in Phase 3 nrSPMS Trial
Tolebrutinib met its primary endpoint in the HERCULES phase 3 trial, delaying confirmed disability progression in non-relapsing secondary progressive multiple sclerosis (nrSPMS) patients, marking a first in this population. The study evaluated the efficacy and safety of tolebrutinib compared to placebo, addressing a significant unmet medical need.
Related Clinical Trials:
Multiple sclerosis pill succeeds in key trial, Sanofi says
Sanofi's tolebrutinib met its key goal in a Phase 3 MS study, potentially leading to regulatory approval, though not all patients saw benefits. The positive result boosts investor confidence in Sanofi's R&D capabilities.
Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first ...
Tolebrutinib met primary endpoint in HERCULES phase 3 study for non-relapsing secondary progressive multiple sclerosis, showing reduction in disability progression. GEMINI 1 and 2 studies in relapsing MS did not meet primary endpoint but showed delay in disability worsening. Results to be discussed with regulatory authorities and presented at ECTRIMS.
Related Clinical Trials:
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of ...
JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.
Common Pitfalls to Avoid When Interpreting Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, a prominent cardiologist, discussed common pitfalls in interpreting clinical trial data at the ESC Congress 2024. His work, cited over 275,000 times, focuses on pivotal trials like REDUCE-IT and SCORED. Bhatt highlighted the 17-year lag between scientific discovery and its adoption into clinical practice.
Cardurion Pharmaceuticals’ Cardiovascular Trials, Cancer Resisting Monoclonal Antibodies, More
Multiple biotech companies raise significant funding for various drug development and clinical trial initiatives, including Cardurion Pharmaceuticals ($260M for cardiovascular therapies), Formation Bio ($372M for AI drug discovery), Element Biosciences ($277M for DNA sequencing), and others targeting cancer, neurodegenerative diseases, and more.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath